Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Getinge AB (GTN0) Stock Price & Analysis

0 Followers

GTN0 Stock Chart & Stats

€24.40-€0.20(-3.17%)
At close: 5:30 PM GMT+1
€23.5€24€24.5€25Oct 16Nov 5
Day’s Range
EUR 24.40 - EUR 24.40
52-Week Range
EUR 15.90 - EUR 25.40
Previous Close
EUR 25.20
Volume
N/A
Average Volume (3M)
1
Market Cap
EUR 6.70B
Enterprise Value
EUR 7.58B
Total Cash (Recent Filing)
EUR 3.19B
Total Debt (Recent Filing)
EUR 11.23B
Price to Earnings (P/E)
26.1
Beta
0.77
Next Earnings
Jan 26, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
1.84%

Bulls Say, Bears Say

Bulls Say

Recurring And High-margin Mix

Recurring revenue at about two-thirds of sales provides a meaningful base of ongoing demand, while the 70% high-margin mix and stronger disposable exposure can support profitability. This should make earnings less dependent on individual capital-equipment projects over the next several quarters.

Sustained Margin Improvement

The sustained improvement in adjusted EBITA margin indicates that pricing, productivity, mix and operating execution are improving underlying profitability. Management’s 16% to 19% target by 2028 provides a multi-year framework for further margin expansion, although delivery remains important.

Strong Cash Flow And Balance Sheet

Strong free cash flow combined with low adjusted leverage gives Getinge financial flexibility to fund investment, support its installed base and pursue opportunities without excessive balance-sheet strain. This resilience can help the company manage uneven hospital and life-science purchasing cycles.

Bears Say

Life Science Weakness

Continued weakness in washer, isolator and sterilizer products is a durable drag on the Life Science segment, with positive bioprocessing and service performance not fully offsetting declines. Lower volumes also reduce operating leverage, limiting the segment’s contribution to group growth.

Elevated Quality Costs

Elevated quality costs continue to absorb profitability in Acute Care Therapies and are expected to remain above normal for some time. Although management anticipates improvement, the gradual timetable means cost pressure can persist through the next several quarters and delay full margin realization.

Surgical Perfusion Phaseout

The surgical perfusion phaseout creates a significant structural revenue headwind, reducing sales by roughly SEK 200 million in 2026. Even with the impact excluded from organic guidance, the transition raises the growth burden on continuing businesses and can dilute near-term reported momentum.

Getinge AB News

GTN0 FAQ

What was Getinge AB’s price range in the past 12 months?
Getinge AB lowest stock price was €15.90 and its highest was €25.40 in the past 12 months.
What is Getinge AB’s market cap?
Getinge AB’s market cap is €6.70B.
When is Getinge AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Getinge AB’s earnings last quarter?
Getinge AB released its earnings results on Oct 21, 2026. The company reported €0.244 earnings per share for the quarter.
Is Getinge AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Getinge AB pay dividends?
Getinge AB does not currently pay dividends.
What is Getinge AB’s EPS estimate?
Getinge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Getinge AB have?
Getinge AB has 254,152,370 shares outstanding.
What happened to Getinge AB’s price movement after its last earnings report?
Getinge AB reported an EPS of €0.244 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Getinge AB?
Currently, no hedge funds are holding shares in DE:GTN0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology